Tilray (TLRY) Scheduled to Post Quarterly Earnings on Thursday

Tilray (NASDAQ:TLRYGet Free Report) is scheduled to post its quarterly earnings results before the market opens on Thursday, October 10th. Analysts expect Tilray to post earnings of ($0.05) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Tilray (NASDAQ:TLRYGet Free Report) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $229.90 million for the quarter, compared to the consensus estimate of $226.20 million. Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. Tilray’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.15) earnings per share. On average, analysts expect Tilray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tilray Stock Performance

NASDAQ:TLRY opened at $1.68 on Thursday. The company has a quick ratio of 1.42, a current ratio of 2.27 and a debt-to-equity ratio of 0.10. Tilray has a twelve month low of $1.50 and a twelve month high of $2.97. The company has a fifty day moving average of $1.79 and a 200-day moving average of $1.88. The firm has a market capitalization of $1.30 billion, a P/E ratio of -3.78 and a beta of 2.13.

Tilray Company Profile

(Get Free Report)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Featured Articles

Earnings History for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.